natgillin/translations-raw huggingface dataset:
23 26 Communication from the Commission COM (2019) 128 of 11.03.2019 to the European Parliament, the Council and the European Economic and Social Committee: ŇEuropean Union Strategic Approach to Pharmaceuticals in the EnvironmentÓ. 
26 Sporočilo Komisije COM (2019) 128 z dne 11. marca 2019 Evropskemu parlamentu, sveti in Evropskemu ekonomsko-socialnemu odboru – Strateški pristop Evropske unije k farmacevtskim izdelkom v okolju.
Some Member States have deployed successful strategies to reduce the use of antibiotics in veterinary medicine 38 The consumption of antimicrobials by food producing animals is much higher than in humans28, whether in terms of total consumption, or in terms of doses compared with weight. 
23 Nekatere države članice so uvedle uspešne strategije za zmanjšanje uporabe antibiotikov v veterinarski medicini 38 Poraba antimikrobikov pri živalih za proizvodnjo živil je veliko večja kot pri ljudeh28, kar velja za celotno porabo in za odmerke glede na težo.
European agencies have recognised that the reduction of the use of veterinary antimicrobials is a desirable objective to contain AMR. 
Evropske agencije so priznale, da je zmanjšanje uporabe antimikrobikov v veterinarski medicini želeni cilj, s katerim bi se omejilo razširjanje protimikrobne odpornosti.
The European Medicines Agency has reported that sales of veterinary antimicrobials, in relation to total livestock (expressed as mg sold per Population Correction Unit (PCU))29 dropped by 20 %30 for the EU as a whole between 2011 and 2016; but also that there were large differences in sales and use of different classes of antimicrobials across the EU. 
Po poročilih Evropske agencije za zdravila je prodaja antimikrobikov za uporabo v veterinarski medicini glede na skupno število glav živine (izražena v prodanih mg na populacijsko korekcijsko enoto (PKE)29 v EU kot celoti upadla za 20 %30 med letoma 2011 in 2016, poleg tega pa so bile pri prodaji in uporabi različnih razredov antimikrobikov v EU velike razlike.
In six Member States, sales of antimicrobials increased by more than 5 %. 
V šestih državah članicah se je prodaja antimikrobikov povečala za več kot 5 %.
Annex I shows detailed sales per country. 
V Prilogi I so navedeni podrobni podatki o prodaji po državah.
Figure 6 shows that sales in the Member States of veterinary antimicrobial agents, expressed as mg sold per PCU31 varied widely. 28 See Table 5 of the most recent JIACRA report (from 2017) on the consumption of antimicrobial agents and occurrence of antimicrobial resistance in bacteria from humans and food producing animals. 
Iz slike 6 je razvidno, da se je prodaja 28 Glej tabelo 5 najnovejšega poročila o skupni medagencijski analizi porabe antimikrobikov in protimikrobne odpornosti (iz leta 2017) (v angleščini) o porabi protimikrobnih sredstev in pojavu protimikrobne odpornosti pri človeških bakterijah in bakterijah živali, ki so namenjene za proizvodnjo živil.
29 ŇPopulation Correction UnitsÓ are used to reflect the size of the animal population and weight of different species. 
29 S populacijskimi korekcijskimi enotami se izrazi velikost živalske populacije in teža različnih živalskih vrst.
30 European Medicines Agency, ŇSales of veterinary antimicrobial agents in 30 European countries in 2016 Đ Trends from 2010 to 2016Ó, Eighth ESVACS report, London, 2018, p. 
30 Evropska agencija za zdravila, Sales of veterinary antimicrobial agents in 30 European countries in 2016 – Trends from 2010 to 2016, osmo poročilo ESVAC, London, 2018, str.
24 Figure 6 Đ Sales of veterinary antimicrobial agents for food producing animals vary widely across Member States Note: EMAadvisedinitsrecentESVACreportnottousedatatodirectlycomparecountries. 
Slika 6 – Prodaja veterinarskih protimikrobnih sredstev za uporabo pri živalih za proizvodnjo živil se med državami članicami zelo razlikuje Opomba: EMA je v svojem nedavnem poročilu ESVAC svetovala, naj se podatki ne uporabljajo za neposredno primerjanje držav.
2016 sales as mg per Population Correction Unit. Source: Adapted from Table 4 8th ESVAC report, EMA. 39 We visited the competent authorities in four Member States to discuss their experiences aimed at achieving a more prudent use of antimicrobials in veterinary medicine. 
Prodaja leta 2016 v mg na populacijsko korekcijsko enoto najvišja 453 povprečna Vir: Prirejeno po tabeli 4 osmega poročila ESVAC, EMA 39 Sodišče je obiskalo pristojne organe v štirih državah članicah, da bi razpravljalo o njihovih izkušnjah v prizadevanjih za preudarnejšo uporabo antimikrobikov v veterinarski medicini.
Box 3 shows some of the good practices they followed to achieve results. Highest 453 Average 129 12 Lowest 25 
V okviru 3 so prikazane nekatere dobre prakse, ki so jih uporabile, da bi dosegle želene rezultate. 129 12 najnižja 31 Glej tabelo 4 osmega poročila ESVAC.
The new EU legal framework addressed some known weaknesses 40 The new EU Regulations on veterinary medicinal products32 and medicated feed33 will strengthen the approach in fighting AMR (see Box 4), by requiring the more prudent use of antimicrobials by the Member States, and regulating the data collection 32 Regulation (EU) 2019/6 of the European Parliament and of the Council of 11 December 2018 on veterinary medicinal products and repealing Directive 2001/82/EC. 
V novem pravnem okviru EU so obravnavane nekatere znane slabosti 40 Z novima uredbama EU o zdravilih za uporabo v veterinarski medicini32 in o medicirani krmi33 se bo okrepil pristop v boju zoper protimikrobno odpornost (glej okvir 4), saj je v njiju določeno, da morajo države članice preudarneje uporabljati antimikrobike, poleg tega pa se z njima ureja okvir za zbiranje podatkov. Komisija 32 Uredba (EU) 2019/6 Evropskega parlamenta in Sveta z dne 11. decembra 2018 o zdravilih za uporabo v veterinarski medicini in razveljavitvi Direktive 2001/82/ES (Besedilo velja za EGP).
33 Regulation (EU) 2019/4 of the European Parliament and of the Council of 11 December 2018 on the manufacture, placing on the market and use of medicated feed, amending Regulation (EC) No 183/2005 of the European Parliament and of the Council and repealing Council Directive 90/167/EEC. 
33 Uredba (EU) 2019/4 Evropskega parlamenta in Sveta z dne 11. decembra 2018 o proizvodnji, dajanju v promet in uporabi medicirane krme, spremembi Uredbe (ES) št. 183/2005 Evropskega parlamenta in Sveta ter razveljavitvi Direktive Sveta 90/167/EGS.
26 Box 3 Member States can reduce the use of veterinary antimicrobials Sweden has the lowest rate of consumption of veterinary antimicrobials in the EU. 
26 Okvir 3 Države članice lahko zmanjšajo uporabo antimikrobikov v veterinarski medicini Švedska ima najnižjo stopnjo porabe antimikrobikov za uporabo v veterinarski medicini v EU.
A focus on animal health, welfare and biosecurity at farms contributed to this. 
K temu je prispevala pozornost, posvečena zdravju živali, dobrobiti živali in biološki zaščiti na kmetijah.
Infection prevention and control plans are mandatory for all farms, antimicrobials are used only on prescription, and national data on the use of veterinary antimicrobials has been collected for many years. 
Načrti za preprečevanje in obvladovanje okužb so obvezni za vse kmetije, antimikrobiki se uporabljajo samo na recept, nacionalni podatki o uporabi antimikrobikov v veterinarski medicini pa se zbirajo že vrsto let.
In the Netherlands, France and especially Spain, the historic use of veterinary antimicrobials was high. 
Na Nizozemskem, v Franciji in zlasti Španiji je bila uporaba antimikrobikov za veterinarsko medicino v preteklosti velika.
The use of veterinary antimicrobials in both France and the Netherlands approximately halved between 2011 and 2016. 
V Franciji in na Nizozemskem se je med letoma 2011 in 2016 zmanjšala za približno polovico.
Although Spain achieved a reduction of 13 % between 2014 and 2016, it remained one of the Member States with a very high use of veterinary antimicrobials. 
Čeprav je Španija med letoma 2014 in 2016 dosegla 13-odstotno zmanjšanje, je še vedno ena od držav članic z zelo veliko uporabo antimikrobikov za veterinarsko medicino.
While the situation is different in each of these countries, the actions taken included setting specific national reduction targets and plans; organising close cooperation between farmers, veterinarians and food producers; and restricting the use of last resort antibiotics in the veterinary sector. 
Razmere so v vsaki od teh držav sicer drugačne, vendar so bili med sprejetimi ukrepi določitev posebnih nacionalnih ciljev in načrtov zmanjšanja, organiziranje tesnega sodelovanja med kmeti, veterinarji in proizvajalci hrane ter omejitev uporabe antibiotikov zadnje izbire v veterinarskem sektorju.
A specific case: significant reduction in the use of colistin in Spain Colistin is a last-resort antibiotic that should only be used under specific circumstances (see paragraph 03). 
Poseben primer: znatno zmanjšanje uporabe kolistina v Španiji Kolistin je antibiotik zadnje izbire, ki naj bi se uporabljal le v posebnih okoliščinah (glej odstavek 03).
In 2014, Spain had the highest veterinary use of colistin in the EU (using 37 mg / PCU). 
Leta 2014 je Španija uporabila največ kolistina za veterinarske namene v EU (in sicer 37 mg/PKE).
An action plan was launched and competent authorities worked with veterinarians and professionals representing the pig farming sector to agree on reducing the use of colistin. 
Uveden je bil akcijski načrt in pristojni organi so sodelovali z veterinarji in strokovnjaki, ki zastopajo sektor prašičereje, da bi se dogovorili o zmanjšanju uporabe kolistina.
A quantitative target of 5 mg/PCU was set for a three-year period, while also putting in place controls to avoid increased use of alternative antibiotics. 
Količinski cilj 5 mg/PKE je bil določen za obdobje treh let, hkrati pa je bil uveden tudi nadzor, da bi se preprečila večja uporaba alternativnih antibiotikov.
The use of colistin dropped to 7 mg/PCU by the start of 2018 (close to the EU average). 
Uporaba kolistina se je do začetka leta 2018 zmanjšala na 7 mg/PKE (blizu povprečja EU).
The Commission plans to adopt implementing and delegated acts to complete the new EU framework in this area by early 2022. 
namerava sprejeti izvedbene in delegirane akte za dokončanje novega okvira EU na tem področju do začetka leta 2022.
27 Box 4 Main weaknesses for AMR addressed in new EU Regulations for veterinary medicinal products and medicated feed The new regulations will in particular: Ń ban the preventive use of antibiotics in groups of animals, and restrict the metaphylactic use of antimicrobials; Ń reinforce an existing ban on using antimicrobials as growth promoters in feed; Ń ban the preventive use of antimicrobials through medicated feed; Ń introduce an option to reserve certain antimicrobials for human use only; Ń require Member States to deliver detailed data on sales and use of antimicrobials that reflect consumption at farm level (in addition to the current voluntary system to collect data based on total sales); Ń require third countries to comply with certain restrictions for their exports to the EU (respecting the ban on antimicrobials for promoting growth and increasing yield, and the restrictions on antimicrobials designated as reserved for human use in the EU). 
27 Okvir 4 Glavne slabosti v zvezi s protimikrobno odpornostjo, ki so bile obravnavane v novih uredbah EU o zdravilih za uporabo v veterinarski medicini in medicirani krmi Z novima uredbama se bo zlasti: — prepovedala preventivna uporaba antibiotikov pri skupinah živali in omejila metafilaktična uporaba antimikrobikov, — poostrila sedanja prepoved uporabe antimikrobikov kot pospeševalcev rasti, — prepovedala preventivna uporaba antimikrobikov prek medicirane krme, — uvedla možnost, da se uporaba nekaterih antimikrobikov omeji samo na ljudi, — od držav članic zahtevalo, da priskrbijo podrobne podatke o uporabi antimikrobikov na ravni kmetij (poleg sedanjega prostovoljnega sistema za zbiranje podatkov na podlagi skupne prodaje), — od tretjih držav zahtevalo, da upoštevajo nekatere omejitve pri svojem izvozu v EU (in spoštujejo prepoved uporabe antimikrobikov za spodbujanje rasti in povečanje donosnosti, ter omejitve pri antimikrobikih, katerih uporaba je v EU omejena na ljudi).
41 However, we found that there are challenges ahead for the Commission and the Member States in rolling out this framework. 
41 Sodišče je ugotovilo, da lahko Komisija in države članice pričakujejo izzive pri vzpostavljanju tega okvira.
In particular, the summary of product characteristics for the use of old medicines, including antimicrobials, need to be updated so they can continue to be used. 
Zlasti je treba posodobiti povzetke glavnih značilnosti zdravila za uporabo starih zdravil, tudi antimikrobikov, da bi se lahko še naprej uporabljala.
42 In addition, Member States will need to collect data on the sales and use of antimicrobials, to evaluate directly or indirectly the use of such products in food producing animals at farm level. 
42 Poleg tega bodo morale države članice zbirati podatke o prodaji in uporabi antimikrobikov, da bodo lahko neposredno ali posredno ocenile uporabo takih proizvodov v živalih za proizvodnjo živil na ravni kmetij.
During our visits to the Member States, we noted that collecting farm-level data was a major challenge. 
Med obiski držav članic je Sodišče ugotovilo, da je zbiranje podatkov na ravni kmetij velik izziv.
Some Member States may need support from the Commission to develop a data collection system to meet the new EU requirements. 
Nekatere države članice bodo morda potrebovale podporo Komisije pri razvoju sistema za zbiranje podatkov, da bi lahko izpolnile nove zahteve EU.
At the time of the audit, the Commission was exploring options for providing such support. 
V času revizije je Komisija preučevala možnosti za zagotavljanje take podpore.
43 In the proposal for a future common agricultural policy (CAP)34 the Commission indicated that its intention was to improve the response of EU agriculture to societal demands on food and health, including on antimicrobial resistance. 
43 Komisija je v predlogu za prihodnjo skupno kmetijsko politiko (SKP)34 navedla, da namerava izboljšati odziv kmetijstva EU na družbene zahteve v zvezi s hrano in zdravjem, vključno s protimikrobno odpornostjo.
The prevention of AMR will be part of the compulsory scope of the farm advisory services, and national authorities will be required to offer advice on the farm practices preventing the development of AMR as set out in the CommissionŐs One Health Action Plan. 
Preprečevanje protimikrobne odpornosti bo del obveznega področja delovanja služb za kmetijsko svetovanje, nacionalni organi pa bodo morali ponujati nasvete o kmetijskih praksah, s katerimi se prepreči razvoj protimikrobne odpornosti, kot je določeno v akcijskem načrtu Komisije „eno zdravje”.
Monitoring of certain resistant bacteria in food and animals has improved, but gaps remain 44 The Member States we visited implemented the requirements contained in the relevant Commission Decision35 on the monitoring and reporting of antimicrobial resistance. 
Spremljanje nekaterih odpornih bakterij v živilih in živalih se je izboljšalo, vendar vrzeli ostajajo 44 Države članice, ki jih je obiskalo Sodišče, so izvajale zahteve iz zadevnega sklepa Komisije35 o spremljanju odpornosti zoonotskih in komenzalnih bakterij proti protimikrobnim snovem in poročanju o njej.
We noted that they performed additional surveillance going beyond the EU requirements. 
Sodišče je ugotovilo, da so izvajale dodaten nadzor, ki je presegal zahteve EU.
However, we also noted certain risk areas that merit consideration in the context of the planned revision of this Commission Decision, which we summarise in Box 5. 
Opozorilo pa je tudi na nekatera področja tveganja, ki bi jih bilo treba upoštevati v okviru načrtovane revizije sklepa Komisije in so povzeta v okviru 5.
28 34 Commission proposal establishing rules on support for strategic plans to be drawn up by Member States under the Common agricultural policy (CAP Strategic Plans) COM(2018) 392. 
28 34 Predlog Komisije o določitvi pravil o podpori za strateške načrte, ki jih pripravijo države članice v okviru skupne kmetijske politike (strateški načrti SKP) , COM(2018) 392.
35 2013/652/EU: Commission Implementing Decision of 12 November 2013 on the monitoring and reporting of antimicrobial resistance in zoonotic and commensal bacteria. 
35 2013/652/EU: Izvedbeni sklep Komisije z dne 12. novembra 2013 o spremljanju in poročanju odpornosti zoonotskih in komenzalnih bakterij proti protimikrobnim snovem.
45 The CommissionŐs right to inspect Member StatesŐ implementation of the AMR monitoring framework is one of the few firm pathways available to the Commission to check how Member States apply AMR veterinary related actions, and support their better implementation. 
45 Pravica Komisije za opravljanje inšpekcijskih pregledov o tem, kako države članice izvajajo okvir za spremljanje protimikrobne odpornosti, je eden od redkih utrjenih načinov, ki so ji na voljo za preverjanje, kako države članice uporabljajo ukrepe, povezane s protimikrobno odpornostjo na področju veterinarske medicine, in podpiranje njihovega boljšega izvajanja.
Commission reports are publicly available37. 
Poročila Komisije so javno dostopna37.
Between 2014 and 2018, the Commission examined 14 Member States, including three38 of the four Member States we visited in the course of this audit. 
Komisija je med letoma 2014 in 2018 preučila 14 držav članic, vključno s tremi38 od štirih držav članic, ki jih je Sodišče obiskalo med to revizijo.
We found that Commission work was of good quality and contributed to improvements in the national monitoring frameworks. 
Sodišče je ugotovilo, da je delo Komisije dobre kakovosti in je prispevalo k izboljšanju nacionalnih okvirov za spremljanje.
The Commission suspended its visits at the end of 2018, as it considered that the primary objectives of the audit work had been met, and as it planned to revise the monitoring and reporting framework. 
Komisija je svoje obiske na koncu leta 2018 začasno prekinila, saj je menila, da so bili glavni cilji revizijskega dela doseženi, in ker je nameravala pregledati okvir za spremljanje in poročanje.
37 The CommissionŐs DG SANTE publishes its reports. 
37 Generalni direktorat Komisije za zdravje in varnost hrane objavlja svoja poročila.
38 Spain, France, the Netherlands. 
38 Španija, Francija in Nizozemska.
29 Box 5 Risk areas for the future EU framework on the monitoring and reporting of antimicrobial resistance in zoonotic and commensal bacteria There are health risks related with AMR stemming from third country food imports, and in particular aquaculture products and fresh meat, but insufficient data is available to assess the seriousness of the risk and whether specific EU requirements for monitoring AMR in these products is needed. 
29 Okvir 5 Področja tveganja za prihodnji okvir EU o spremljanju protimikrobne odpornosti zoonotskih in komenzalnih bakterij in poročanju o njej S protimikrobno odpornostjo so povezana zdravstvena tveganja, ki izhajajo iz uvoza hrane iz tretjih držav, zlasti proizvodov ribogojstva in svežega mesa, vendar ni na voljo dovolj podatkov za oceno resnosti tveganja in o tem, ali so potrebne posebne zahteve EU za spremljanje protimikrobne odpornosti v teh proizvodih.
We note that similar issues were also addressed in a 2019 scientific report from EFSA36. 
Sodišče opaža, da so bila podobna vprašanja obravnavana tudi v znanstvenem poročilu agencije EFSA iz leta 201936.
The current EU monitoring and reporting requirements cover cattle, pigs and poultry for meat consumption which are the most commonly consumed species for the EU as a whole. 
Sedanje zahteve EU glede spremljanja in poročanja zajemajo govedo, prašiče in perutnino za mesno prehrano, kar so najpogosteje zaužite živalske vrste v EU kot celoti.
In some parts of Europe species other than those covered by the 2013 Commission Decision such as ducks, rabbits, goats and sheep are also frequently consumed. 
V nekaterih delih Evrope se poleg živalskih vrst, zajetih v Sklepu Komisije iz leta 2013, pogosto uživajo tudi druge, kot so race, kunci, koze in ovce.
Some countries may perform monitoring of AMR in food originating from these species but this is not required by the EU framework. 
Nekatere države lahko izvajajo spremljanje protimikrobne odpornosti v živilih, ki izvirajo iz teh vrst, vendar to v okviru EU ni obvezno.
The EU budget provides significant support for AMR research but this has not yet resulted in major breakthroughs 46 The research and development of new antimicrobials, alternative treatments and vaccines is a highly complex and very important element in the fight against AMR. 
Proračun EU zagotavlja znatno podporo raziskavam na področju protimikrobne odpornosti, vendar to še ni privedlo do pomembnih prebojev 46 Raziskave in razvoj novih antimikrobikov, alternativnih zdravljenj in cepiv so izredno kompleksna in zelo pomembna sestavina boja zoper protimikrobno odpornost.
We examined whether research efforts followed a strategic approach and addressed key challenges, while encouraging sustainable results. 
Sodišče je preučilo, ali je bil pri raziskovalnih prizadevanjih privzet strateški pristop in ali so bili obravnavani ključni izzivi, hkrati pa spodbujani trajnostni rezultati.
The Commission coordinates AMR research efforts but has not comprehensively evaluated its approach 47 In its 2017 Action Plan the Commission reported that it had spent over Ű1.3 billion on AMR research since the start of the 2000-2006 programming period. 
Komisija usklajuje raziskovalna prizadevanja na področju protimikrobne odpornosti, vendar svojega pristopa ni celovito ocenila 47 Komisija je v svojem akcijskem načrtu iz leta 2017 poročala, da je od začetka programskega obdobja 2000–2006 porabila več kot 1,3 milijarde EUR za raziskave na področju protimikrobne odpornosti.
In addition, JU IMI allocated Ű367 million to the New Drugs for Bad Bugs Programme (ND4BB). 
Poleg tega je Skupno podjetje IMI dodelilo 367 milijonov EUR projektu „nova zdravila za slabe bacile”.
The EU budget finances at least as much on AMR research as all EU Member States combined. 
Raziskave na področju protimikrobne odpornosti se financirajo vsaj toliko iz proračuna EU, kot zanje namenijo vse države članice EU skupaj.
The Commission takes an active role in coordinating its R&D efforts internationally (e.g. G20 hub for AMR Research and Development, Transatlantic Taskforce on AMR, JPIAMR). 
Komisija dejavno sodeluje pri usklajevanju svojih prizadevanj na področju raziskav in razvoja na mednarodni ravni (npr. pri vozlišču za raziskave in razvoj na področju protimikrobne odpornosti v okviru skupine G20, Čezatlantski delovni skupini proti antimikrobični odpornosti ter skupni načrtovalni pobudi za zajezitev protimikrobne odpornosti).
48 The majority of the Commission funded research effort was on the search to develop new antimicrobials, alternative treatments and vaccines. 
48 Raziskovalna prizadevanja, ki jih financira Komisija, so bila povečini usmerjena v raziskave za razvoj novih antimikrobikov, alternativnih zdravljenj in cepiv.
This funding uses grant payments, which help ŇpushÓ ideas for new drugs through development phases (see Figure 7 below) and ultimately to their commercialisation. 
Za to financiranje se uporabljajo plačila nepovratnih sredstev, ki pripomorejo k temu, da se zamisli za nova zdravila potisnejo skozi razvojne faze (glej sliko 7 v nadaljevanju) in končno v fazo njihovega trženja.
This funding is exposed to high risks, because AMR research is inherently complex; the commercial industries 30 have largely lost their appetite to invest in this area (see paragraph 07); and there are currently no specific ŇpullÓ economic incentives (such as market entry rewards and long term supply continuity models). 
To financiranje je izpostavljeno velikim tveganjem, saj so raziskave na področju protimikrobne odpornosti po svoji naravi kompleksne, komercialne panoge pa so povečini izgubile zanimanje za naložbe na tem področju (glej odstavek 07) in trenutno ni specifičnih pritegnitvenih ekonomskih spodbud (kot so nagrade za vstop na trg in dolgoročni sistemi neprekinjene dobave).